Why Early-Stage Funding

It is often difficult to bring breakthroughs from basic academic research to the patient, or “from bench to bed”. After academic funding and before classic seed financing for early clinical trials, there is a gap, often referred to as the “valley of death”. In this transitional phase, when findings from basic research mature into lead compounds for clinical testing, development projects are particularly vulnerable due to insufficient funding.